CD274 and breast carcinoma: While the FDA has granted an accelerated approval for atezolizumab, a monoclonal antibody drug targeting PD-L1, plus chemotherapy for the treatment of TNBC14, the potential application of immune therapies for patients with luminal breast cancer remains largely unknown.